The conference will be held October 18 to 21 at McCormick Place.
Q2-2014 procedures declined 1.4 percent year over year and 2.9 percent compared with Q1-2014.
Responses to our Q2-2014 survey indicate a recovery from the weather-impacted first quarter.
In a conference call, Alimera Sciences discussed its plans to market its DME treatment following FDA regulatory approval.
The implant was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant or who are scheduled for cataract surgery.
The advisory meeting is set for November 14 in Gaithersburg, MD.
As the drugmaker’s battle with Valeant continues, the focus now turns to a special meeting of shareholders in December.
Once such merger has already been scuttled: Salix Pharmaceuticals’ acquisition of Italy’s Cosmo Pharmaceuticals.
The former head of Advanced Medical Optics is under fire in a case involving a former major league baseball player.
In its two Phase III clinical trials, the treatment met the primary endpoint of non-inferiority with once-daily dosing versus twice-daily dosing of timolol maleate.
You are not currently logged in.
©2017 Market Scope
Lost your Password